

## New material for covering chronic wounds

### Development status

#### Phase 3


**Technology validation and implementing it in real environment.** Testing the technology outside of the laboratory and its adjustment to external conditions.

### IP protection status

CZ patent application filed

### Partnering strategy

*Collaboration, licensing*



### Institution



UNIVERSITY  
OF PARDUBICE

University of Pardubice

### Challenge

Non-healing wounds are a worldwide problem, especially in diabetics. Wounds are usually infected with microorganisms that form a very resistant so-called biofilm and have an alkaline pH. Thus, wound protection should simultaneously “acidify” and disinfect the wound environment. There are wound covers or various gels for chronic wounds available on the market. Wound covers are often based on a silver disinfectant (newly in nano-form), but the silver is physiologically non-degradable. Gels containing sodium hyaluronate and iodine are also available. Their disadvantage is instability over time. The offered technology brings a solution in the form of a “spinnable” stable complex of iodine with starch containing a physiologically acceptable acidifying component.

### Description

The developed wound covers are based on staple microfibers made of sodium hyaluronate and oxidized starch, which also contain physiologically acceptable acid. The wound cover is a sheet, where the diameter of the fibrils is 200 nm - 15 μm, the length of the fibrils is 0.5 - 10 cm, and the surface weight of the cover is 10 - 30 g/m<sup>2</sup>. Iodine can also be introduced into the cover as a disinfectant, which forms a very stable complex with the oxidised starch over time. The shelf life is over 3 years.

### Commercial opportunity

End customers are hospitals, medical practices, but also patients in home care or beauty salons. Technology and production of wound covers must be operated by a company capable of manufacturing medical devices, companies producing bandages and plasters, or a regular pharmaceutical company.